Search Results - "Biagini, I. M."

  • Showing 1 - 2 results of 2
Refine Results
  1. 1
    Tabalumab in Rheumatoid Arthritis Patients With an Inadequate Response to Methotrexate and Naive to Biologic Therapy: A Phase II, Randomized, Placebo‐Controlled Trial

    Tabalumab in Rheumatoid Arthritis Patients With an Inadequate Response to Methotrexate and Naive to Biologic Therapy: A Phase II, Randomized, Placebo‐Controlled Trial by Genovese, M. C., Bojin, S., Biagini, I. M., Mociran, E., Cristei, D., Mirea, G., Georgescu, L., Sloan‐Lancaster, J.

    Published in Arthritis & rheumatology (Hoboken, N.J.) (01-04-2013)
    “…Objective Tabalumab, a fully human IgG4 monoclonal antibody, neutralizes soluble and membrane‐bound BAFF. The aim of this study was to examine the tolerability…”
    Get full text
    Journal Article
    Save to List
    Saved in:
  2. 2
    LY2439821, a humanized anti–interleukin‐17 monoclonal antibody, in the treatment of patients with rheumatoid arthritis: A phase I randomized, double‐blind, placebo‐controlled, proof‐of‐concept study

    LY2439821, a humanized anti–interleukin‐17 monoclonal antibody, in the treatment of patients with rheumatoid arthritis: A phase I randomized, double‐blind, placebo‐controlled, proof‐of‐concept study by Genovese, M. C., Van den Bosch, F., Roberson, S. A., Bojin, S., Biagini, I. M., Ryan, Peter, Sloan‐Lancaster, J.

    Published in Arthritis and rheumatism (01-04-2010)
    “…Objective We undertook this study to evaluate safety, tolerability, pharmacokinetics, pharmacodynamics, and efficacy of LY2439821, a humanized…”
    Get full text
    Journal Article
    Save to List
    Saved in:

Search Tools: